Theodore Gancayco, MD
Ophthalmology · Washington, DCNPI 1932217262
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 95 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $742, 2.0 times the $366 reported in 2019.
Across 95 payments — averaging $23.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tarsus Pharmaceuticals, Inc.$483
- Sun Pharmaceutical Industries Inc.$231
- Alcon$221
- AbbVie$218
- Bausch & Lomb Americas Inc.$214
- Novartis$199
- plus $648 from 13 others
What the payments were for
- Food & beverage$2,214100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tarsus Pharmaceuticals, Inc. | 22 | $483 |
| Sun Pharmaceutical Industries Inc. | 10 | $231 |
| Alcon | 9 | $221 |
| AbbVie(2 entities) | 9 | $218 |
| Bausch & Lomb Americas Inc. | 10 | $214 |
| Novartis | 11 | $199 |
| Shire North American Group Inc | 1 | $123 |
| Oyster Point Pharma, Inc. | 5 | $119 |
| Dompe US, Inc. | 4 | $111 |
| Amgen(2 entities) | 3 | $64 |
| Kala Pharmaceuticals, Inc. | 2 | $41 |
| Astellas Pharma US Inc | 1 | $35 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $27 |
| Genentech USA, Inc. | 1 | $26 |
| Apellis Pharmaceuticals, Inc. | 1 | $22 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $21 |
| Harrow Eye, LLC | 1 | $18 |
| Sight Sciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIIDRA$123
How this compares
$2,214 in reported general payments places this provider in the 60th percentile of 74 ophthalmology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 66 | $54,309 |
| RestasisCyclosporine | 41 | $53,238 |
| XiidraLifitegrast | 26 | $47,601 |
| LumiganBimatoprost | 63 | $37,748 |
| Travoprost | 159 | $35,381 |
| RhopressaNetarsudil Mesylate | 32 | $22,083 |
| Alphagan PBrimonidine Tartrate | 27 | $17,977 |
| Latanoprost | 1,258 | $16,938 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 28 | $14,828 |
| Brimonidine Tartrate | 154 | $11,934 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 61 | $11,744 |
| Cyclosporine | 17 | $9,829 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 279 | $7,844 |
| Timolol Maleate | 207 | $7,771 |
| CombiganBrimonidine Tartrate/Timolol | 17 | $7,645 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $218 | $116,607148 claims |
| Bausch & Lomb Americas Inc.Xiidra | $214 | $47,60126 claims |
| AlconSimbrinza | $221 | $14,82828 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $27 | $2,45811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 74 ophthalmology providers in District of Columbia.
Other ophthalmology in Washington
- Wiley ChambersWashington$618K
- Keesha Williams ElliottWashington$167K
- Samuel StopakWashington$33K
- Jonca BullWashington$30K
- Leslie JonesWashington$22K
- Alexander HacopianWashington$13K
- Mehdi Tavakoli DastjerdiWashington$12K
- Andrew HammerWashington$11K
- Thandeka MyeniWashington$10K
- Dipak PanigrahiWashington$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.